Gilead Sciences Licenses Respiratory and Herpes Antiviral Research Programs From Novartis
July 19 2019 - 8:30AM
Business Wire
Gilead Sciences, Inc. (NASDAQ: GILD) announced today that it has
licensed three preclinical antiviral programs from Novartis,
including investigational agents with the potential to treat human
rhinovirus, influenza and herpes viruses.
Under the agreement, Gilead will acquire exclusive global rights
to develop and commercialize novel small molecules against three
undisclosed targets. Novartis will receive an upfront payment and
is eligible to receive up to an additional $291 million in
potential milestone payments upon achievement of certain
development and commercial milestones, as well as royalties on
annual net sales.
“Today’s announcement builds on Gilead’s heritage in antiviral
research and development. We look forward to applying this
expertise to advance the development of potential new treatments
for viruses with limited therapeutic options,” said John
McHutchison AO, MD, Gilead’s Chief Scientific Officer and Head of
Research and Development.
Gilead’s antiviral portfolio includes among the most widely used
medicines for the treatment of HIV, hepatitis B and hepatitis C, as
well as influenza infection.
About Gilead Sciences
Gilead Sciences, Inc. is a research-based biopharmaceutical
company that discovers, develops and commercializes innovative
medicines in areas of unmet medical need. The company strives to
transform and simplify care for people with life-threatening
illnesses around the world. Gilead has operations in more than 35
countries worldwide, with headquarters in Foster City,
California.
For more information on Gilead Sciences, please visit the
company’s website at www.gilead.com.
Forward-Looking
Statement
This press release includes forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of 1995
that are subject to risks, uncertainties and other factors,
including the risk that Gilead may fail to advance any of the
preclinical antiviral programs licensed from Novartis. All
statements other than statements of historical fact are statements
that could be deemed forward-looking statements. These risks,
uncertainties and other factors could cause actual results to
differ materially from those referred to in the forward-looking
statements. The reader is cautioned not to rely on these
forward-looking statements. These and other risks are described in
detail in Gilead’s Quarterly Report on Form 10-Q for the quarter
ended March 31, 2019, as filed with the U.S. Securities and
Exchange Commission. All forward-looking statements are based on
information currently available to Gilead, and Gilead assumes no
obligation to update any such forward-looking statements.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20190719005073/en/
Ryan McKeel, Media (650) 377-3548
Gilead Sciences (NASDAQ:GILD)
Historical Stock Chart
From Mar 2024 to Apr 2024
Gilead Sciences (NASDAQ:GILD)
Historical Stock Chart
From Apr 2023 to Apr 2024